ADME Services | ADME/Tox Testing Services | Corning

We use cookies to ensure the best experience on our website.
View Cookie Policy
Accept Cookie Policy
Change My Settings
Required for the site to function.
Augment your site experience.
Lets Corning work with partners to enable social features and marketing messages.

The ADME services you need to make important drug-development decisions.

Take your ADME/Tox testing to completion

Founded in 1992, we stand ready to become an extension of your ADME teamor your virtual ADME partnerto help strengthen your ability to meet your drug discovery and pre-clinical goals.

  • Full range of ADME/Tox services: From permeability, drug absorption, and transport to drug metabolism our services fully support your comprehensive ADME/Tox testing needs.
  • Long track record of success: For more than 20 years, the Corning Gentest Contract Research team has been successfully developing and conducting in vitro drug-drug interaction studies, contributing to hundreds of pharmaceutical discovery and development programs for many of the world's leading pharmaceutical and biotech companies.
  • Skilled Study Directors: Our scientists are experts in the areas of drug absorption, transporters, metabolism, induction, toxicity, and industry/regulatory guidance. We'll work with you to facilitate informed decisions.
  • Alignment with regulatory guidance: Study designs are continually updated to be aligned with current Regulatory Agency guidance. So you can be assured you’ll have the right data for submission to the FDA, EMA, and MHLW-PWDA.
  • Superior Quality: All services are conducted in Corning's GLP-compliant and ISO 9001-certified laboratories. You can depend on our team for accurate, reproducible data and regulatory submission-ready reports.
  • Customization: Whether modifying our standard protocols or adapting the protocols of our clients, Corning has the expertise needed to offer customized solutions to meet your specific needs.

ADME Services

Transporter Interactions

From screening assays to comprehensive drug-drug interaction assessment, we can provide solutions to your ABC efflux and SLC uptake transporter assay needs. We offer diverse study models and assays which comply with FDA/EMA recommended approaches to determine cell permeability and evaluate your compounds as substrates and/or inhibitors of P-gp, BCRP, BSEP, MRPs, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1, MATE2-K, and more.  

Enzyme Inhibition

Our CYP and UGT inhibition services are conducted with Corning UltraPool® HLM 150 pooled human liver microsomes, drug probe substrates and validated LC/MS/MS methods. Options include direct and time-dependent inhibition studies with flexible endpoints. Kinetic results reported include IC50, IC50 shift (dilution and non-dilution methodology), as well as KI and kinact. Assays are also available using hepatocytes or recombinant enzyme study models.

Enzyme Induction

For 20+ years, we have provided regulatory agency-driven cytochrome P450 (CYP) induction services using primary hepatocytes. Testing options include enzyme activity and mRNA endpoints for CYP1A2, CYP2B6, CYP3A4, CYP2C8, CYP2C9, CYP2C19, UGTs, and more. Data may include EC50, Emax or relative induction scores (RIS). Rapid and conventional assay protocols are available which can be modified to your needs.

Reaction Phenotyping

Using our well-known Corning Supersomes™ enzymes, human liver microsomes, or hepatocytes, we will evaluate enzyme-mediated pathways of elimination for your compound. Enzyme-selective chemical inhibitors and/or immunoinhibitory antibodies can be used to confirm pathways and evaluate whether your compound could be a “victim” of drug-drug interactions.

Screening – Discovery Compounds

Corning provides additional services, including rapid in vitro metabolic stability, intrinsic clearance, permeability, and plasma protein binding. Our metabolic stability studies utilize several different enzyme sources - hepatocytes, S9 or liver microsomes obtained from human and preclinical species. Enzyme sources feature carefully selected donors or donor pools to maintain data consistency. For more information, contact us for a discussion.

NEW Services

  • Cytochrome P450 (CYP) induction screening using primary human hepatocytes
  • Cytochrome P450 (CYP) reversible and time-dependent inhibition (TDI) in human hepatocytes
  • Contribution of aldehyde oxidase (AO) and CYPs to metabolic clearance in human hepatocytes
  • UGT inhibition


Coming Soon

  • Cytochrome P450 (CYP) induction screening Corning HepatoCells

Custom Assays